NCT00004770已完成不适用
Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy
National Center for Research Resources (NCRR)0 个研究点目标入组 1 人开始时间: 1995年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1
研究概览
简要总结
OBJECTIVES:
I. Assess the efficacy of thioctic acid in treating a single patient with mitochondrial myopathy.
详细描述
PROTOCOL OUTLINE: The patient receives one thioctic acid tablet 3 times a day. If patient experiences no side effects after 1 week, 2 tablets are administered and given 3 times a day over 3 months for compassionate use.
The patient is followed at weeks 3, 8, and 12.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 0 Years 至 —(Child, Adult, Older Adult)
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics--
- •Long standing ophthalmoparesis and fatiguable weakness of the limbs
- •Mild ataxia and no central nervous system involvement
- •History of mitochondrial DNA deletion and a measurable biochemical defect of the respiratory chain
- •Steady deterioration in skeletal muscle mass and power over 5 years
- •-Prior/Concurrent Therapy--
- •Previous participation in studies of muscle disease natural history (CRC Protocol 183A)
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)Diabetic PolyneuropathyNCT00977483MEDA Pharma GmbH & Co. KG460
已完成
2 期
The Use of a Mitochondrial Enhancement Treatment in Bipolar DisorderBipolar DepressionNCT00719706Mclean Hospital40
已完成
1 期
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's DiseaseAlzheimer Disease, Early OnsetNCT04552795The University of Texas Health Science Center at San Antonio12
已完成
3 期
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)Diabetic PolyneuropathyNCT00328601MEDA Pharma GmbH & Co. KG170
已完成
1 期
4'-Thio-araC (Thiarabine) in Advanced Hematologic MalignanciesLeukemiaNCT01139151M.D. Anderson Cancer Center31
